KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions®, a leader in the development of innovative and minimally invasive treatment modalities to address patients suffering from heart failure with functional mitral regurgitation (FMR), today announced that renowned interventional cardiologist Satya Shreenivas, MD, MBA has joined […]
Tag: Cardiac Dimensions
Cardiac Dimensions Receives Medical Device Regulation (MDR) Certification for Carillon Mitral Contour System
KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatment modalities to address patients suffering from heart failure with functional mitral regurgitation (FMR), today announced that its Carillon Mitral Contour System® has received certification under Regulation (EU) 2017/745 […]
Cardiac Dimensions Appoints Angie Swenson as Vice President, Clinical Operations
KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the appointment of Angie Swenson as Vice President of Clinical Operations. Ms. Swenson has spent […]
Cardiac Dimensions Raises $35 Million in Series D Financing
Funds Expected to Support Enrollment in U.S. Pivotal EMPOWER Trial and European Commercial Expansion for Carillon Mitral Contour System® KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular […]
Cardiac Dimensions Included in the New 2021 ESC Guidelines for Heart Failure Management
Guidelines support the Carillon Mitral Contour System® for the treatment of heart failure patients with secondary functional mitral regurgitation KIRKLAND, Wash., Sept. 22, 2021 /PRNewswire/ — Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure […]
Cardiac Dimensions® Announces Launch of Its Optimized U.S. Pivotal Trial – The EMPOWER Trial
International Study to Evaluate Innovative Minimally Invasive Treatment for Heart Failure With Early-Stage Functional Mitral Regurgitation KIRKLAND, Wash., Aug. 20, 2021 /PRNewswire/ — Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and […]
Data Published in “JACC Heart Failure”Show Benefit of Carillon Device to Patients Suffering from Functional Mitral Regurgitation & Severe Left Ventricular
On behalf of Cardiac Dimensions, please find key outcomes of the analysis “Percutaneous Mitral-Valve Annuloplasty Versus Optimal Medical Therapy in Patients with Secondary Mitral-Regurgitation and Severe Left-Ventricular Enlargement” published in this month’s JACC: Heart Failure. The manuscript can be viewed here: https://cardiacdimensions.com/wp-content/uploads/docs/Anker-Complete-Publication_May-2021.pdf Key outcomes […]
Cardiac Dimensions Announces Two New Meta-Analysis Publications Showing Statistically Significant and Clinically Meaningful Benefits to Heart Failure Patients Suffering from Functional Mitral Regurgitation
KIRKLAND, Wash., April 7, 2021 /PRNewswire/ — Cardiac Dimensions announced a published second individual patient data meta–analysis demonstrating clinically significant outcomes for the Carillon Mitral Contour System®. This publication, in addition to the several others recently published on the Carillon device, continues the […]
Cardiac Dimensions Welcomes Robert White to its Board of Directors
KIRKLAND, Wash., April 6, 2021 /PRNewswire/ — Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today announced the election of Robert White as an independent director to its Board of […]
Percutaneous Coronary Sinus–Based Mitral Valve Annuloplasty in Atrial Functional Mitral Regurgitation
Atrial functional mitral regurgitation (aFMR) is associated with left atrial (LA) and mitral annular dilatation most often caused by atrial fibrillation or heart failure with preserved ejection fraction (HFpEF). (A) Echocardiographic assessment, (B) functional mitral regurgitation classification, (C) New York […]